微小RNAs在心肌肥厚中作用和分子机制的研究进展

doi:10.16352/j.issn.1001-6325.2023.07.1167

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1167-1170.doi: 10.16352/j.issn.1001-6325.2023.07.1167

微小RNAs在心肌肥厚中作用和分子机制的研究进展

王帆, 邓勇志^*

山西医科大学附属心血管病医院山西省心血管病医院山西省心血管病临床医学研究中心心血管外科, 山西太原 030024

收稿日期:2022-03-03 修回日期:2022-11-13 出版日期:2023-07-05 发布日期:2023-07-05
通讯作者: ^*olympicschina@163.com

Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy

WANG Fan, DENG Yongzhi^*

Department of Cardiovascular Surgery, Shanxi Cardiovascular Hospital, the Affiliated Cardiovascular Hospital of Shanxi Medical University, the Clinical Medical Research Center of Shanxi Province, Taiyuan 030024, China

Received:2022-03-03 Revised:2022-11-13 Online:2023-07-05 Published:2023-07-05

摘要/Abstract

摘要： 微小RNAs(miRNAs)是一类非编码RNAs,与多种心血管疾病相关,包括高血压、心力衰竭和心肌梗死等。miRNAs的表达在心肌肥厚过程中通过调节心肌细胞自噬、炎性反应和能量代谢等过程调控心肌肥厚。

关键词: 心肌肥厚, 微小RNA, 作用靶点, 信号通路

Abstract: MicroRNAs(miRNAs) are a class of non-coding RNAs associated with a variety of cardiovascular diseases, including hypertension, heart failure and myocardial infarction. Expression of miRNAs changes during cardiac hypertrophy, which regulates cardiac hypertrophy by regulating cardiomyocyte autophagy, inflammatory response and energy metabolism. This article reviews the expression changes, potential targets and molecular mechanisms of miRNAs in cardiac hypertrophy.

Key words: cardiac hypertrophy, microRNA, target of action, signal pathway

中图分类号:

王帆, 邓勇志. 微小RNAs在心肌肥厚中作用和分子机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1167-1170.

WANG Fan, DENG Yongzhi. Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy[J]. Basic & Clinical Medicine, 2023, 43(7): 1167-1170.

参考文献

[1] 《中国心血管健康与疾病报告2020》概述[J].中国心血管病研究,2021, 19: 582-590.
[2] Colpaert RMW, Calore M. MicroRNAs in cardiac diseases[J]. Cells, 2019, 18, 8: 737.doi:10.3390/cells8070737.
[3] Tu YF, Wan L, Bu LH, et al. MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention[J]. Cell Physiol Biochem, 2013, 31: 997-1008.
[4] Yang XY, Tao LH, Zhu J, et al. Long noncoding RNA FTX reduces hypertrophy of neonatal mouse cardiac myocytes and regulates the PTEN/PI3K/Akt signaling pathway by sponging microRNA-22[J]. Med Sci Monit, 2019, 25: 9609-9617.
[5] Kopechek JA, McTiernan CF, Chen X, et al. Ultrasound and microbubble-targeted delivery of a microRNA inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function[J]. Theranostics, 2019, 9: 7088-7098.
[6] Yang JJ, Nie Y, Wang F, et al. Reciprocal regulation of miR-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy[J]. Biochim Biophys Acta, 2013, 1831: 1386-1394.
[7] Yang J, Xu J, Han X, et al. Lysophosphatidic acid is associated with cardiac dysfunction and hypertrophy by suppressing autophagy via the LPA3/AKT/mTOR pathway[J].Front Physiol, 2018, 9:1315.doi:10.3389/fphys.2018.01315.
[8] Li Z, Song Y, Liu L, et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation[J]. Cell Death Differ, 2017, 24: 1205-1213.
[9] Yan HL, Wang H, Zhu XX, et al. PGC-1alphaAdeno-associated virus-mediated delivery of anti-miR-199a tough decoys attenuates cardiac hypertrophy by targeting[J]. Mol Ther Nucleic Acids, 2021, 23: 406-417.
[10] Duygu B, Poels EM, Juni R, et al. miR-199b-5p is a regulator of left ventricular remodeling following myocardial infarction[J]. Noncoding RNA Res, 2017, 2: 18-26.
[11] Zhou Y, Li KS, Liu L, et al. MicroRNA132 promotes oxidative stressinduced pyroptosis by targeting sirtuin 1 in myocardial ischaemiareperfusion injury[J].Int J Mol Med, 2020, 45:1942-1950.
[12] Man AWC, Li H, Xia N.The role of sirtuin1 in regulat-ing endothelial function, arterial remodeling and vascular aging[J].Front Physiol, 2019, 10:1173.doi:10.3389/fphys.2018.01315.
[13] Li F, Li SS, Chen H, et al. miR-320 accelerates chronic heart failure with cardiac fibrosis through activation of the IL6/STAT3 axis[J]. Aging (Albany NY), 2021, 13: 22516-22527.
[14] Jia GZ, Liang CG, Li WH, et al. miR-410-3p facilitates Angiotensin Ⅱ-induced cardiac hypertrophy by targeting Smad7[J]. Bioengineered, 2022, 13: 119-127.
[15] Shi JY, Chen C, Xu X, et al. miR-29a promotes pathological cardiac hypertrophy by targeting the PTEN/AKT/mTOR signalling pathway and suppressing autophagy[J]. Acta Physiol (Oxf), 2019, 227: 13323.doi:10.1111/apha.13323.
[16] Kura B, Kalocayova B, LeBaron TW, et al. Regulation of microRNAs by molecular hydrogen contributes to the prevention of radiation-induced damage in the rat myocardium[J]. Mol Cell Biochem, 2019, 457: 61-72.
[17] He R, Ding C, Yin P et al. miR-1a-3p mitigates isoproterenol-induced heart failure by enhancing the expression of mitochondrial ND1 and COX1.[J].Exp Cell Res, 2019, 378: 87-97.
[18] Zhao L, Li W, Zhao H.Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p.[J]. Am J Transl Res, 2020, 12: 718-730.
[19] Yuan Y, Wang J, Chen QX, et al. Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865: 1421-1427.
[20] Long YD, Wang L, Li ZQ.SP1-induced SNHG14 aggravates hypertrophic response in in vitro model of cardiac hypertrophy via up-regulation of PCDH17.[J].J Cell Mol Med, 2020, 24: 7115-7126.
[21] Salamon I, Biagini E, Kunderfranco P, et al. Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson-Fabry disease[J]. Cell Death Dis, 2021, 12: 1150.doi:10.1038/s41419-021-04438-5.
[22] Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, et al. A novel circulating microRNA for the detection of acute myocarditis[J]. N Engl J Med, 2021, 384: 2014-2027.
[23] Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study[J]. Eur Heart J, 2021, 42: 178-188.

微小RNAs在心肌肥厚中作用和分子机制的研究进展

Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[2]	蒋苏, 吕新翔, 崔艳红, 吕李婷, 李东霞. 吴茱萸碱对特应性皮炎模型大鼠的治疗作用[J]. 基础医学与临床, 2024, 44(9): 1256-1262.
[3]	金庆, 丁佑铭. FOXC1在消化系统癌发生发展中作用的研究进展[J]. 基础医学与临床, 2024, 44(7): 1049-1053.
[4]	高寅洁, 童安莉. 醛固酮产生腺瘤中细胞死亡和增殖机制[J]. 基础医学与临床, 2024, 44(6): 758-762.
[5]	何华美, 陆巍. miR-135a-5p通过调控CXCL12表达降低吗啡耐受[J]. 基础医学与临床, 2024, 44(5): 665-672.
[6]	徐璐, 张冬雨, 王瑞锋. 茯苓酸调节PI3K/AKT/NF-κB信号通路对大鼠幽门螺旋杆菌相关性胃炎的治疗作用[J]. 基础医学与临床, 2024, 44(4): 489-495.
[7]	韩丽杰, 胡朝伟, 于华惠, 秦彦文. 血管生成素样蛋白8在心血管疾病发病中作用的研究进展[J]. 基础医学与临床, 2024, 44(4): 544-547.
[8]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[9]	韩惠晶, 吴红, 葛银, 乔娟. 右美托咪定减轻呼吸机相关性肺损伤模型大鼠肺组织损伤[J]. 基础医学与临床, 2024, 44(3): 339-345.
[10]	陈卫卫, 廖煌, 史振鸿, 罗颖. FHL2通过NF-κB信号通路调节THP-1巨噬细胞泡沫化[J]. 基础医学与临床, 2024, 44(2): 204-209.
[11]	李炜康, 李东宝, 任嘉裕, 孙小童, 段开鹏, 周进. Ghrelin在胃癌中的作用[J]. 基础医学与临床, 2024, 44(10): 1460-1464.
[12]	邓娟, 王秀芳, 孙瑞青. 汉黄芩素促进自身免疫性肝炎模型大鼠Th17/Treg细胞平衡[J]. 基础医学与临床, 2024, 44(1): 77-83.
[13]	潘闪, 林铿强, 陈树兴. 培美曲塞抑制人肺腺癌细胞系A549增殖[J]. 基础医学与临床, 2023, 43(9): 1359-1363.
[14]	韩晶晶, 王萱若, 张欣怡, 高涵, 成秀梅, 杨留才, 曲学彬. 转录因子CREB调节小鼠CD4⁺淋巴细胞中miR-30a的表达[J]. 基础医学与临床, 2023, 43(8): 1229-1233.
[15]	王琼, 董倩兰, 朱燕亭, 金刚, 张琳萍. 桔梗皂苷D减轻大鼠肾缺血/再灌注损伤[J]. 基础医学与临床, 2023, 43(8): 1222-1228.